Acceptability Assessment of an "Organization of Care Integrating Artificial Intelligence and a Solution of Telemedicine" on Care of the Nursing Home Residents Located in a Medical Desert: Pilot Study INTEL@MED-POC (Intel@Med-Poc)

While depend elderly people needs are important in Nursing Home, the medical resources are weak from both inside and outside residences located in a medical desert. The goal of this project is to measure the acceptability of Artificial Intelligence and Telemedicine in Nursing Home located in medical desert for patients, nurses, and medical doctor

Study Overview

• Status: Recruiting
• Conditions: Homes for the Aged
• Intervention / Treatment: Other: Telemedecine

Detailed Description

The ageing of the population comes along with the problematic of chronic pathologies and dependence, with sometimes serious consequences resulting in an admission in Nursing Home. While the low require a medical doctor in each Nursing Home, one third of the Nursing Home does not have. Some Nursing Homes can be in a tricky situation with no medical doctor coordinator and the difficulty of access to a medical doctor who covered a wide territory. In this context, the emergence of Artificial Intelligence coupled with Telemedicine is a new opportunity to find solution in healthcare organization and to develop advanced geriatric medical practice in medical desert territory. The goal of this study is to quantify and characterize the acceptability of Artificial Intelligence and Telemedicine in Nursing Home located in medical desert for patients, nurses, and medical doctor.

All the patients were examined by a nurse. The symptoms filled by the nurse in the Artificial Intelligence/Telemedicine device are sent and then analyzed by a distant medical doctor to purpose a care. The nurse also solicited the attending medical doctor as usual care.

The recommendations of the both medical doctors could be (i) Vital emergency, (ii) non-vital emergency necessitate medication or hospitalization, and (iii) non-emergency with medical appointment.

• Study Type: Interventional
• Enrollment (Anticipated): 308
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Achille TCHALLA, MD; Phone Number: +33555058894; Email: achille.tchalla@chu-limoges.fr

Study Locations

• France
  • Auzances, France, 23700
    • Not yet recruiting
    • EHPAD Le Bois Joli
    • Contact: Emmanuelle Gaillard, Nurse; Phone Number: 05.55.67.73.30
  • Chambon-sur-Voueize, France, 23170
    • Not yet recruiting
    • EHPAD Le Chant des Rivières
    • Contact: Marina Blondonnet, Nurse; Phone Number: 05.55.82.11.02
  • La Roche Chalais, France, 24490
    • Not yet recruiting
    • EHPAD La Porte d'Aquitaine
    • Contact: Remi Rambonona, Nurse; Phone Number: 05.53.91.41.30
  • Merlines, France, 19340
    • Recruiting
    • Ehpad Le Chavanon
    • Contact: Sandrine Malgat, Nurse; Phone Number: 07.55.64.50.73; Email: telemedecine@pompidou-merlines.fr
  • Peyrelevade, France, 19290
    • Recruiting
    • EHPAD Ernest Coulaud
    • Contact: Raphaël Bessaudou, Nurse; Phone Number: 05.55.94.72.85; Email: rbessaudou@mutualitelimousine.fr
  • Saint Privat, France, 19220
    • Recruiting
    • EHPAD J et M Colaud
    • Contact: Aurélie Malarange, Nurse; Phone Number: 05.55.28.26.54; Email: direction.ehpadstprivat@orange.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 65 years and older (OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient older than 65 years old.
• Patient living in Nursing Home located in medical desert.
• Patient presenting symptoms involved medical doctor call.
• Patient or legal representative having signed consent form
• Patient covered by social security

Exclusion Criteria:

• End of life patient.
• Chronic aphasic patient.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Active arm; use of telemedicine	Other: Telemedecine; telemedical consultation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Acceptability for nurse to use Artificial Intelligence / Telemedecine device analyzed by distant medical doctor	Proportion of the Artificial Intelligence / Telemedecine utilization by the nurse vs medical doctor as usual care	13 months
Number of non-programmed hospitalization for both distant medical doctor and usual care recommendations	Comparison of non programmed hospitalization in both distant medical doctor analysis and medical doctor as usual care	13 months
delay to obtain the medical expertise	Comparison of time to obtain the medical expertise for distant medical doctor and usual care recommandations	13 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
sensitivity and specificity of diagnostic	Calculation of sensitivity and specificity of diagnostic for acute disease and emergency for both distant medical doctor and usual care recommendations	13 months

Collaborators and Investigators

• Sponsor: University Hospital, Limoges

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 15, 2020
• Primary Completion (ANTICIPATED): March 25, 2023
• Study Completion (ANTICIPATED): March 25, 2023

Study Registration Dates

• First Submitted: December 3, 2020
• First Submitted That Met QC Criteria: December 17, 2020
• First Posted (ACTUAL): December 22, 2020

Study Record Updates

• Last Update Posted (ACTUAL): April 4, 2022
• Last Update Submitted That Met QC Criteria: April 1, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: telemedicine; artificial intelligence; aged
• Other Study ID Numbers: 87RI18-0018/Intel@Med-Poc

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No